These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10796065)

  • 1. Imipenem but not meropenem induces convulsions in DBA/2 mice, unrelated to cerebrospinal fluid concentrations.
    Dupuis A; Pariat C; Courtois P; Couet W; Bouquet S
    Fundam Clin Pharmacol; 2000; 14(2):163-5. PubMed ID: 10796065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice.
    de Sarro A; Imperatore C; Mastroeni P; de Sarro G
    J Pharm Pharmacol; 1995 Apr; 47(4):292-6. PubMed ID: 7791026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
    Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
    Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cerebrospinal fluid diffusion of imipenem and meropenem in rats.
    Dupuis A; Caillaud A; Pariat C; Courtois P; Couet W; Bouquet S
    J Pharm Pharmacol; 2000 Sep; 52(9):1143-9. PubMed ID: 11045896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Different Carbapenem Antibiotics (Ertapenem, Imipenem/Cilastatin, and Meropenem) on Serum Valproic Acid Concentrations.
    Wu CC; Pai TY; Hsiao FY; Shen LJ; Wu FL
    Ther Drug Monit; 2016 Oct; 38(5):587-92. PubMed ID: 27322166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem/cilastatin as empirical treatment of severe infections in compromised patients.
    Biglino A; Bonasso M; Gioannini P
    J Chemother; 1991 Jan; 3 Suppl 1():208-12. PubMed ID: 12041767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem: evidence of lack of proconvulsive tendency in mice.
    Patel JB; Giles RE
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():307-9. PubMed ID: 2808213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem.
    Day IP; Goudie J; Nishiki K; Williams PD
    Toxicol Lett; 1995 Apr; 76(3):239-43. PubMed ID: 7762010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin.
    Böswald M; Döbig C; Kändler C; Krüger C; Scharf J; Soergel F; Zink S; Guggenbichler JP
    Infection; 1999; 27(4-5):299-304. PubMed ID: 10885853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem-cilastatin in the treatment of hospital infections.
    Mao P; Enrichens F; Olivero G; Sciascia C; Benedetto G; Franchello A; Olivero S
    J Chemother; 1991 Jan; 3 Suppl 1():205-7. PubMed ID: 12041766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
    Kuti JL; Florea NR; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effects of meropenem and imipenem/cilastatin on some functions of human natural effector cells.
    Cornacchione P; Scaringi L; Capodicasa E; Fettucciari K; Rosati E; Sabatini R; Benedetti C; Marconi P; Rossi R; Del Favero A
    Chemotherapy; 2000; 46(2):135-42. PubMed ID: 10671765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxic and peroxidative potential of meropenem and imipenem/cilastatin in rat and human renal cortical slices and microsomes.
    Yousif T; Pooyeh S; Hannemann J; Baumann J; Tauber R; Baumann K
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):475-86. PubMed ID: 10543314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
    Verwaest C;
    Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
    Cox CE; Holloway WJ; Geckler RW
    Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
    Tonelli F
    Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
    Colardyn F; Faulkner KL
    J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
    Basoli A; Meli EZ; Mazzocchi P; Speranza V
    Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics.
    Horiuchi M; Kimura M; Tokumura M; Hasebe N; Arai T; Abe K
    Toxicology; 2006 May; 222(1-2):114-24. PubMed ID: 16549226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
    Ong CT; Kuti JL; Nicolau DP;
    Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.